Cara, Maruishi sign licensing deal for analgesic drug
The agreement provides Maruishi with exclusive rights to develop, manufacture and commercialize Cara’s CR845 for acute pain and uremic pruritus indications in Japan. Cara Therapeutics CEO Derek Chalmers
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.